{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:53:03Z","timestamp":1753883583521,"version":"3.41.2"},"reference-count":64,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Neoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy is the gold standard for treating patients with higher risk early triple-negative breast cancer (TNBC); however, in some cases, these patients undergo surgery followed by chemotherapy-based anthracyclines and taxanes without adhering to the guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Patients with previously untreated stage I, II, and III TNBC who received adjuvant therapy with either doxorubicin and cyclophosphamide (AC) + docetaxel (AC-D), AC + weekly paclitaxel (AC-WP), epirubicin and cyclophosphamide (EC) + docetaxel (EC-D), or EC + WP (EC-WP); older than 18 years; and diagnosed between January 1st, 2011, and December 31st, 2022, were eligible for the study. Disease-free survival (DFS) is the primary reported end point. Overall survival (OS) and safety were the secondary end points.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              We included 272 female patients. At a prespecified event-driven data cutoff, with a median follow-up of 26.3 months, the 5-year DFS was 49% (95% CI, 38 to 63) in the AC-D group, 45% (95% CI, 29 to 70) in the AC-WP group, 73% (95% CI, 61 to 100) in the EC-D group, and 72% (95% CI, 44 to 100) in the EC-WP group (hazard ratio [HR], 0.2 [95% CI, 0.06 to 0.67];\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .08). The 7-year OS was 52% (95% CI, 32 to 83) in the AC-D group, 88% (95% CI, 78 to 99) in the AC-WP group, 95% (95% CI, 88 to 100) in the EC-D group, and 83% (95% CI, 58 to 100) in the EC-WP group (HR, 0.19 [95% CI, 0.06 to 0.66];\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .03). Most of the grade 3-4 adverse events occurred in the AC-D group, primarily neutropenia, nausea-vomiting, and alopecia.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>EC-D was linked to a slightly longer survival free of invasive, noninvasive, or distant disease and a significantly longer OS with fewer adverse events. Further studies are needed to confirm and establish long-term clinical benefits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00650","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:59:19Z","timestamp":1746820759000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-0881","authenticated-orcid":true,"given":"Hassan Abdelilah","family":"Tafenzi","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco"},{"name":"Biosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-6288","authenticated-orcid":true,"given":"Farah","family":"Choulli","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco"},{"name":"Biosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Essaadi","sequence":"additional","affiliation":[{"name":"Biosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco"},{"name":"Medical Oncology Department, Avicenna Military Hospital of Marrakech, Marrakech, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco"},{"name":"Biosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S1-01"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390464"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.5005"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0235"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071167"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60740-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.519"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0128-9"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4725"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.2646"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9549"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30111-6"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.506","article-title":"GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel\/carboplatin followed by epirubicin\/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD)","volume":"37","author":"Fasching PA","year":"2019","unstructured":"Fasching PA, Jackisch C, Rhiem K, et al: GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel\/carboplatin followed by epirubicin\/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 37, 2019 (suppl 15; abstr 506)","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01304"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-PD11-01"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.74"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.063"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.517"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043681"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2000.n.002"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-suppl_2-24"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2879"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2341"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1906"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010717"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.314"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.040"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/pr9071086"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.633"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.5858\/134.6.907"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0985-4"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1252230"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.7.564"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-579X(02)00056-1"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03613"},{"key":"e_1_3_4_51_2","unstructured":"U.S. Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE). https:\/\/cir.nii.ac.jp\/crid\/1370017279879487627"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4380-9_25"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.3109\/9780203640661"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-75692-9_6"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1961.10482090"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7841"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.521"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3941"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.081"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2965"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.12.004"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj305"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11616-5"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:59:29Z","timestamp":1746820769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1200\/GO-24-00650"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00650","relation":{},"ISSN":["2687-8941"],"issn-type":[{"type":"electronic","value":"2687-8941"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400650"}}